Mirati Therapeutics

Mirati's long wait for next lung cancer med ends in phase 3 failure
Mirati's long wait for next lung cancer med ends in phase 3 failure
Fierce Biotech
Mirati Therapeutics
clinical trials
sitravantinib
lung cancer
non small cell lung cancer
Flag link:
Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Fierce Pharma
Mirati Therapeutics
Krazati
Amgen
Lumakras
lung cancer
Flag link:
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'
Fierce Biotech
Eli Lilly
Amgen
Mirati Therapeutics
KRAS inhibitors
AACR
Flag link:
FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen
FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen
MedCity News
Amgen
Mirati Therapeutics
Krazati
Lumakras
FDA
lung cancer
Flag link:
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer
Flag link:
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Flag link:
Go or no go? Mirati heads to the FDA
Go or no go? Mirati heads to the FDA
EP Vantage
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
Flag link:
Mirati is once again the subject of Big Pharma takeover talks: report
Mirati is once again the subject of Big Pharma takeover talks: report
Fierce Biotech
Mirati Therapeutics
M&A
Amgen
Lumakras
Flag link:
4 Biotech Stocks With Huge Incoming Catalysts
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
Brace for an end-of-year boost to drug approvals
Brace for an end-of-year boost to drug approvals
EP Vantage
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Flag link:
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
Fierce Biotech
ASCO 2022
Mirati Therapeutics
Amgen
Lumakras
adagrasib
lung cancer
Flag link:
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
BioPharma Dive
Mirati Therapeutics
Amgen
KRAS
adagrasib
Lumakras
clinical trials
Flag link:
AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle
AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle
Fierce Pharma
AACR
Amgen
Lumakras
Mirati Therapeutics
Flag link:
The biggest launches of 2022: a reboot
The biggest launches of 2022: a reboot
EP Vantage
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
Flag link:
Amgen hold-up gives Mirati a vital lifeline
Amgen hold-up gives Mirati a vital lifeline
EP Vantage
Amgen
Mirati Therapeutics
Lumakras
lung cancer
clinical trials
Flag link:
7 drugs likely to hit $1B in annual revenue in the next 5 years
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Flag link:
Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability
Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability
Fierce Biotech
Mirati Therapeutics
Amgen
KRAS
clinical trials
Merck
Keytruda
Flag link:
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Fierce Biotech
Sanofi
Mirati Therapeutics
adagrasib
non-small cell lung cancer
Flag link:
Biogen, mRNA players on Merck's M&A radar as CEO still hungry for deals after $11.5B Acceleron buy: FT
Biogen, mRNA players on Merck's M&A radar as CEO still hungry for deals after $11.5B Acceleron buy: FT
Fierce Pharma
Merck
M&A
Biogen
Mirati Therapeutics
Flag link:

Pages